Abstract:Genome-wide association studies have identified several genetic variants associated with nonalcoholic fatty liver disease. To emphasize metabolic abnormalities in fatty liver, metabolic (dysfunction)-associated fatty liver disease (MAFLD) has been introduced; thus, we aimed to investigate single-nucleotide polymorphisms related to MAFLD and its subtypes. A genome-wide association study was performed to identify genetic factors related to MAFLD. We used a Korean population-based sample of 2282 subjects with MAFLD and a control group of 4669. We replicated the results in a validation sample which included 639 patients with MAFLD and 1578 controls. Additionally, we categorized participants into three groups, no MAFLD, metabolic dysfunction (MD)-MAFLD, and overweight/obese-MAFLD. After adjusting for age, sex, and principal component scores, rs738409 [risk allele G] and rs3810622 [risk allele T], located in the PNPLA3 gene, showed significant associations with MAFLD ( P -values, discovery set = 1.60 × 10 –15 and 4.84 × 10 –10 ; odds ratios, 1.365 and 1.284, validation set = 1.39 × 10 –4 , and 7.15 × 10 –4 , odds ratios, 1.299 and 1.264, respectively). An additional SNP rs59148799 [risk allele G] located in the GATAD2A gene showed a significant association with MAFLD ( P -values, discovery set = 2.08 × 10 –8 and validation set = 0.034, odds ratios, 1.387 and 1.250). rs738409 was significantly associated with MAFLD subtypes ([overweight/obese-MAFLD; odds ratio (95% confidence interval), P -values, 1.515 (1.351–1.700), 1.43 × 10 –12 and MD-MAFLD: 1.300 (1.191–1.416), 2.90 × 10 –9 ]. There was a significant relationship between rs3810622 and overweight/obese-MAFLD and MD-MAFLD [odds ratios (95% confidence interval), P -values, 1.418 (1.258, 1.600), 1.21 × 10 –8 and 1.225 (1.122, 1.340), 7.06 × 10 –6 , respectively]; the statistical significance remained in the validation set. PNPLA3 was significantly associated with MAFLD and MAFLD subtypes in the Korean population. These results indicate that genetic factors play an important role in the pathogenesis of MAFLD.

Interplay of Mediterranean-diet adherence, genetic factors, and metabolic dysfunction-associated steatotic liver disease risk in Korea

Association between dairy-rich dietary pattern and metabolic dysfunction-associated steatotic liver disease: Findings from the Korean Genome and Epidemiology Study

Higher Adherence to the Mediterranean Diet Is Associated with a Lower Risk of Steatotic, Alcohol-Related, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Analysis

Metabolic Outcomes in Non-Alcoholic and Alcoholic Steatotic Liver Disease among Korean and American Adults: A Population-Based Multi-Cohort Study

Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study

Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality

Bioactive Metabolites: a Clue to the Link Between MASLD and CKD?

Metabolic dysfunction-associated steatotic liver disease and risk of esophageal cancer in patients with diabetes mellitus: a nationwide cohort study

Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure

Incidence of metabolic dysfunction‐associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study

Prevalence, incidence, and recovery of metabolic dysfunction-associated steatotic liver disease and associations with weight loss and lipid reduction in a Chinese community-based cohort

Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease

Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes

Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics

The Effect of Mobile Lifestyle Intervention Combined with High-Protein Meal Replacement on Liver Function in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Controlled Trial

Targeting ketone body metabolism to treat fatty liver disease

Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population

Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study

S1910 Differential Effect of Cardiometabolic Risk Factors on Mortality in US Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)